Tannic acid synergizes the cytotoxicity of chemotherapeutic drugs in human cholangiocarcinoma by modulating drug efflux pathways

Journal of Hepatology

Volumn 46, Issue 2, 2007, Pages 222-229

  Naus, Peter J ^a   Henson, Roger ^a   Bleeker, Grant ^a   Wehbe, Hania ^a   Meng, Fanyin ^a   Patel, Tushar ^a  

^a SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

Author keywords

Biliary cancers; Chemotherapy; Pharmacology; Plant polyphenol; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; CALCEIN; FLUOROURACIL; GEMCITABINE; GLYCOPROTEIN P; MITOMYCIN C; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; POLYPHENOL; TANNIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TRANSPORT; HUMAN; HUMAN CELL; MEMBRANE TRANSPORT; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BILE DUCT NEOPLASMS; CELL LINE, TUMOR; CHOLANGIOCARCINOMA; DEOXYCYTIDINE; DOWN-REGULATION; DRUG INTERACTIONS; FLUORESCEINS; FLUOROURACIL; HUMANS; MEMBRANE TRANSPORT PROTEINS; MITOMYCIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; TANNINS;

EID: 33845659501     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2006.08.012     Document Type: Article

References (22)

1. Patel T. Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol 3 (2006) 33-42
2. Sirica A.E. Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology 41 (2005) 5-15
3. Lazaridis K.N., and Gores G.J. Cholangiocarcinoma. Gastroenterology 128 (2005) 1655-1667
4. Khan S.A., Thomas H.C., Davidson B.R., and Taylor-Robinson S.D. Cholangiocarcinoma. Lancet 366 (2005) 1303-1314
5. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 33 (2001) 1353-1357
6. Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2 (2002) 10
7. Khan S.A., Taylor-Robinson S.D., Toledano M.B., Beck A., Elliott P., and Thomas H.C. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol 37 (2002) 806-813
8. Taylor-Robinson S.D., Toledano M.B., Arora S., Keegan T.J., Hargreaves S., Beck A., et al. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut 48 (2001) 816-820
9. Marienfeld C., Tadlock L., Yamagiwa Y., and Patel T. Inhibition of cholangiocarcinoma growth by tannic acid. Hepatology 37 (2003) 1097-1104
10. Direct Food Substances Affirmed as Generally Recognized as Safe. 2002. Report No.: Title 21, 1989, Pt 84.
11. Yamagiwa Y., Meng F., and Patel T. Interleukin-6 decreases senescence and increases telomerase activity in malignant human cholangiocytes. Life Sci 78 (2006) 2494-2502
12. Chou T.C., and Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22 (1984) 27-55
13. Park J., Tadlock L., Gores G.J., and Patel T. Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line. Hepatology 30 (1999) 1128-1133
14. Yamagiwa Y., Marienfeld C., Meng F., Holcik M., and Patel T. Translational regulation of x-linked inhibitor of apoptosis protein by interleukin-6: a novel mechanism of tumor cell survival. Cancer Res 64 (2004) 1293-1298
15. Tadlock L., Yamagiwa Y., Hawker J., Marienfeld C., and Patel T. Transforming growth factor-beta inhibition of proteasomal activity: a potential mechanism of growth arrest. Am J Physiol Cell Physiol 285 (2003) C277-C285
16. De Angelis P.M., Svendsrud D.H., Kravik K.L., and Stokke T. Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery. Mol Cancer 5 (2006) 20
17. Gigliozzi A., Fraioli F., Sundaram P., Lee J., Mennone A., Alvaro D., et al. Molecular identification and functional characterization of Mdr1a in rat cholangiocytes. Gastroenterology 119 (2000) 1113-1122
18. Rost D., Konig J., Weiss G., Klar E., Stremmel W., and Keppler D. Expression and localization of the multidrug resistance proteins MRP2 and MRP3 in human gallbladder epithelia. Gastroenterology 121 (2001) 1203-1208
19. Courtois A., Payen L., Lagadic D., Guillouzo A., and Fardel O. Evidence for a multidrug resistance-associated protein 1 (MRP1)-related transport system in cultured rat liver biliary epithelial cells. Life Sci 64 (1999) 763-774
20. Cao L., Duchrow M., Windhovel U., Kujath P., Bruch H.P., and Broll R. Expression of MDR1 mRNA and encoding P-glycoprotein in archival formalin-fixed paraffin-embedded gall bladder cancer tissues. Eur J Cancer 34 (1998) 1612-1617
21. Mackey J.R., Mani R.S., Selner M., Mowles D., Young J.D., Belt J.A., et al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 58 (1998) 4349-4357
22. Bergman A.M., Pinedo H.M., Talianidis I., Veerman G., Loves W.J., van der Wilt C.L., et al. Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines. Br J Cancer 88 (2003) 1963-1970